An application of MIB antibody to the retrospective study of melanomas of oral mucosa and facial skin

Korabiowska, M; Brinck, Ulrich; Hoenig, Johannes Franz; Bartkowski, S; Mirecka, J; Schauer, A.

doi:10.1007/bf01247462

Cited by 9 publications

(14 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Which problems have to be considered with regard to the determination of these immunohistochemical markers and to our statistical evaluation? A prognostic relationship of the seven significant markers of this study, except H2‐8‐10, has been reported 3,8,11,12,16,19–25,27,30–36 or at least suspected 7,37 , 38 in the literature. Our data, obtained by tests of a larger number of tumours, confirms these earlier results.…”

Section: Discussionsupporting

confidence: 53%

“…The expression of HLA‐DQ and HLA‐DP antigens on primary and metastatic melanomas has been described 18 . The staining characteristics of the proliferation marker Ki‐67 have been studied in primary and metastatic melanomas 3 , 19–28 . The reactivity pattern of antimacrophage antibody EBM‐11 with various tissues, including skin has been described 13…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic immunohistochemical markers of primary human melanomas

et al. 2001

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 53%

Section: Methodsmentioning

confidence: 99%

Prognostic immunohistochemical markers of primary human melanomas

et al. 2001

View full text Add to dashboard Cite

show abstract

“…A correlation between mitotic indices and the Ki-67 positivity in malignant melanomas has been observed by several investigators (40,43,45). Some investigators have also studied the correlation of Ki-67 immunostaining results and tumor size and/ or prognosis in malignant melanoma of the skin (22,23,(40)(41)(42)(43)(44). Tbese studies are summarized in Table 6.…”

Section: Studymentioning

confidence: 88%

“…In primary malignant melanoma of the skin the proliferative activity has also been studied by several methods. In some of these studies mitotic counts, flow cytometry and immunohistochemical staining with Ki-67 antibody have had prognostic value (18)(19)(20)(21)(22)(23). However, to our knowledge, the prognostic value of Ki-67 immunostaining has not been studied utilizing multistep regression analysis models and the follow-up times of the patients have been rather short.…”

mentioning

confidence: 99%

Nuclear morphometry, immunohistochemical staining with Ki‐67 antibody and mitotic index in the assessment of proliferative activity and prognosis of primary malignant melanomas of the skin

1996

View full text Add to dashboard Cite

Nuclear morphometry, immunohistochemical staining with Ki-67 antibody and mitotic index were studied in primary cutaneous malignant melanomas. The number of Ki-67 positive cells/ 200 tumor cells did not correlate with any nuclear morphometrical parameters, and it only approached but did not reach significant correlation with melanoma thickness according to Breslow. The nuclear area, short axis and long axis correlated with melanoma thickness, but the nuclear axis ratio (which reflects the sphericity of nuclei) and melanoma thickness did not show significant correlation. Mitotic index was higher in thick melanomas and in melanomas with high Ki-67 positivity, large nuclear area, long nuclear short axis, and small nuclear axis ratio. In Cox's stepwise proportional hazard model, melanoma thickness and the nuclear axis ratio were significant independent prognostic factors for patient survival, while the nuclear area, short axis and long axis, gender, age, Clark level, mitotic index and Ki-67 positivity lacked significant independent prognostic value. The results suggest that the proliferative activity of tumor cells does not alone explain the great importance of tumor thickness as prognosticator in melanoma. The thickness of melanoma measured according to Breslow and the nuclear axis ratio are more efficient prognosticators in melanoma than parameters associated with proliferation.

show abstract

“…Previous studies of melanoma have investigated the ability of Ki‐67 to provide useful prognostic information 11–16. Because Ki‐67 is not expressed in resting, G0 cells, but is expressed from the mid‐G1 phase of the cell cycle through S, G2, and M phases, it is considered to be a reliable marker of cell proliferation.…”

mentioning

confidence: 99%

Evaluation of the proliferation marker MIB‐1 in the prognosis of cutaneous malignant melanoma

Hazan

Melzer

Panageas

et al. 2002

Cancer

View full text Add to dashboard Cite

BACKGROUND The proliferation marker MIB‐1, which recognizes the Ki‐67 antigen, provides independent prognostic information in several tumor types. Its utility in melanoma has been evaluated mostly in studies of thick primary tumors. Its usefulness in thinner lesions has not been assessed adequately. METHODS A well characterized cohort of 137 patients diagnosed with primary cutaneous melanoma at the New York University School of Medicine between 1972 and 1982 was studied based on the availability of representative tissues and adequate clinical follow‐up. Twenty‐one tumors were less than or equal to 1.0 mm thick, 94 were between 1.01 and 4.0 mm thick, and 22 were thicker than 4.0 mm. Tumor cell proliferation was assessed by immunohistochemistry using the monoclonal antibody MIB‐1. MIB‐1 expression was correlated with baseline clinicopathologic parameters, as well as recurrence (RR), disease‐free (DFS), and overall survival (OS) rates. Median follow‐up among survivors was 6.5 years (range, 5.6–17.5). RESULTS High proliferative index, defined as 20% or more of tumor cells showing nuclear immunoreactivity, was observed in 65 of 137 (47.4%) cases. High proliferative index was significantly correlated with increased tumor thickness (P < 0.001) and higher stage (P = 0.03). Trends approaching statistical significance were observed with ulceration of the primary tumor (P = 0.09), male gender (P = 0.06), and shorter DFS (P = 0.12). No significant associations were seen between high proliferative index and RR or OS. In multivariate analyses, tumor thickness was the strongest predictor of clinical outcome. CONCLUSIONS In primary cutaneous melanoma, a high proliferative index is associated with clinicopathologic parameters predictive of worse clinical outcomes. However, it was not an independent predictor of clinical outcome. Cancer 2002;95:634–40. © 2002 American Cancer Society. DOI 10.1002/cncr.10685

show abstract

An application of MIB antibody to the retrospective study of melanomas of oral mucosa and facial skin

Cited by 9 publications

References 13 publications

Prognostic immunohistochemical markers of primary human melanomas

Prognostic immunohistochemical markers of primary human melanomas

Nuclear morphometry, immunohistochemical staining with Ki‐67 antibody and mitotic index in the assessment of proliferative activity and prognosis of primary malignant melanomas of the skin

Evaluation of the proliferation marker MIB‐1 in the prognosis of cutaneous malignant melanoma

Contact Info

Product

Resources

About